Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Daclizumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daclizumab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daclizumab.
Advertisement
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Daclizumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Daclizumab.
Belimumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.
Advertisement
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.
Fingolimod
Daclizumab may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.
Advertisement
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.
Leflunomide
The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Daclizumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daclizumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Daclizumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Daclizumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Daclizumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Daclizumab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Daclizumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
Tofacitinib
Daclizumab may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Daclizumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Daclizumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Daclizumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Daclizumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Daclizumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Daclizumab.
